Seoul District Court Defends LG Non-Compete Contract, Puts Brakes On Samsung Manhunt For Biosimilar Specialists
This article was originally published in The Pink Sheet Daily
Former LG Life Sciences VP Kim Kyu-Don is key to Samsung's biosimilar plans, but the court ruled he must wait until Feb. 28, 2011, to take the job or pay KRW2 million ($1,620) per day to work in defiance of the court's decision.
You may also be interested in...
SEOUL - Samsung Group has ended years of exploration for new business realms beyond its traditional pipeline of semiconductors and electronics products; South Korea's leading conglomerate is set to enter the healthcare sector, particularly biosimilars and medical devices, with an initial investment of roughly $4.1 billion
Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition
SEOUL - South Korea's leading biosimilar companies such as LG Life Sciences, Celltrion and others are increasingly wary of Samsung Electronics' ongoing talent search for research and development experts as the company prepares to make its debut in the blooming biosimilar business
SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs